Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Bevacizumab + Chemo in NSCLC with Brain Metastases
NCT05812534Phase 2Unknown
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Overall Response Rate at 6 weeks. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05812534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812534.